Company Overview
Company Type: Public Company
Website: fusionpharma.com
Number of Employees: 101
Ticker: FUSN (NasdaqGS)
Year Founded: 2014


Business Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.5
Market Capitalization
325.6
TEV/Total Revenue
246.1x
EBITDA
(135.0)
Total Enterprise Value
123.9
TEV/EBITDA
NM
EBIT
(136.5)
Cash & ST Invst.
271.0
P/Diluted EPS Before Extra
NM
Net Income
(134.2)
Total Debt
69.2
Price/Tang BV
1.2x
Capital Expenditure
(4.2)
Total Assets
367.0
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.55)
(0.58)
(2.31)
(2.29)
(2.34)
Revenue (mm)
0.12
0.67
0.30
5.32
1.03
EBITDA (mm)
(39.39)
(42.02)
(149.18)
(183.03)
(171.82)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
NM
TEV/EBITDA
NM
P/BV
2.74x

Non-Periodic Estimates

Recommendation
Buy (1.17)
Target Price
17.92
Potential Upside
279.71%


Key Professionals
Name
Title
Valliant, John F.
Founder, CEO & Director
Rawat, Mohit 
President & Chief Business Officer
Crowley, John J.
Chief Financial Officer
Burak, Eric 
Chief Technology Officer
Leamon, Christopher Paul
Chief Scientific Officer
Cray, Amanda 
Senior Director of Investor Relations & Corporate Communications
Stahl, Maria D.
Chief Legal Officer
Bobilev, Dmitri 
Chief Medical Officer
Ferreira, Cara 
Chief of Staff
Hoffman, Eric S.
Senior Vice President of Business Development
Schindler, Joanne 
Executive Vice President of Medical Director & Clinical Development

Key Board Members
Name
Title
Duncan, Barbara G.
Independent Chairperson of the Board
Valliant, John F.
Founder, CEO & Director
Cagnoni, Pablo J.
Independent Director
Gannon, Steven R.
Independent Director
Bergstrom, Donald A.
Independent Director
Christenson, Johan 
Independent Director
Juergens, Rosalyn 
Member of Advisory Board
Khuntia, Deepak 
Member of Advisory Board
Khuong, Chau Quang
Independent Director
Lee, Philina 
Independent Director
O’Bryan-Tear, Gillies 
Member of Advisory Board
Preston, Heather 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
270 Longwood Road South | Hamilton, ON | L8P 0A6 | Canada
Phone: 289 799 0891   

Current and Pending Investors
Adams Street Partners, LLC (Elisha Gould), Avidity Partners Management, L.P., Canada Pension Plan Investment Board, Deerfield Management Company, L.P. Series C, Federated Hermes, Inc. (NYSE:FHI), Fidelity Management & Research Company LLC, Fight Against Cancer Innovation Trust, Genesys Capital Partners Inc., Johnson & Johnson Innovation - JJDC, Inc., Lumira Ventures, Millennium Management LLC, Nan Fung Life Sciences, Odlander, Fredrikson & Co. AB, OrbiMed Advisors LLC, Pivotal BioVenture Partners LLC (Heather Preston), Rock Springs Capital Management LP, Seroba Life Sciences Limited (Alan O’Connell), Teralys Capital, The Invus Group, LLC, TPG Biotech, Varian Medical Systems, Inc., Woodline Partners LP

Prior Investors
Fight Against Cancer Innovation Trust, Investment Arm, Perceptive Advisors LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 4.58
Market Cap (mm)
325.6
Open
 4.65
Shares Out. (mm)
69.0
Previous Close
 4.72
Float %
75.0%
Change on Day
(0.14)
Shares Sold Short (mm)
0.1
Change % on Day
(2.9)%
Dividend Yield %
-
Day High/Low
 4.77/ 4.40
Diluted EPS Excl. Extra Items
(2.57)
52 wk High/Low
 7.70/ 2.71
P/Diluted EPS Before Extra
NM
Volume (mm)
0.13
Avg 3M Dly Vlm (mm)
0.08
Beta 5Y
(1.10)


 
Delayed Quote** | Last Updated on Oct-06-2023 12:10 PM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Niowave Inc. (Pending)
Niowave Inc. researches and manufactures superconducting particle accelerators and their components. It offers niobium, niobium cavities, superconducting magnets, accelerator systems and cryomodules, electron guns and injectors, RRR testing products, and cryogenics. Niowave Inc. was founded in 2005 and is based in Lansing, Michigan.

United States and Canada
Heavy Electrical Equipment
-
-
-
CPDC patents and patent applications (Pending)

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-16-2023
-
Shelf Registration
Target
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)

Federated Hermes, Inc. (NYSE:FHI)
22.20
May-10-2023
-
Private Placement
Target
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
Federated Hermes, Inc. (NYSE:FHI)

20.00
Mar-16-2023
-
Shelf Registration
Target
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)

Perceptive Advisors LLC,The Invus Group, LLC,Woodline Partners LP,Avidity Partners Management, L.P.,Federated Hermes, Inc. (NYSE:FHI),Fidelity Select Portfolios - Biotechnology Portfolio (MutualFund:FBIO.X),Fidelity Management & Research Company LLC,Fidelity Advisor Series VII - Fidelity Advisor Biotechnology Fund (MutualFund:FBTI.X),Deerfield Management Company, L.P. Series C,Millennium Management LLC Seller Funds:Woodline Master Fund LP, Avidity Master Fund LP, Avidity Private Master Fund I LP, Deerfield Partners, LP, Perceptive Life Sciences Master Fund, Ltd., Invus Public Equities, L.P., Integrated Core Strategies (US) LLC, ICS Opportunities, Ltd
74.12
Mar-16-2023
-
Shelf Registration
Target
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)


16.13
Feb-10-2023
-
Private Placement
Target
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
Perceptive Advisors LLC,Woodline Partners LP,Avidity Partners Management, L.P.,Federated Hermes, Inc. (NYSE:FHI) Buyer Funds:Woodline Master Fund LP

44.79
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-13-2023
Company Conference Presentations
Fusion Pharmaceuticals Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 03:35 PM
Sep-12-2023
Company Conference Presentations
Fusion Pharmaceuticals Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-12-2023 02:00 PM
Jul-27-2023
Company Conference Presentations
Fusion Pharmaceuticals Inc. Presents at 2nd Annual Targeted Radiopharmaceuticals Summit, Jul-27-2023 12:30 PM
Jun-27-2023
Special Calls
Fusion Pharmaceuticals Inc. - Special Call
Jun-26-2023
Product-Related Announcements
Fusion Pharmaceuticals Inc. to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
Private Placement Advisors
Jefferies Group LLC, Morgan Stanley (NYSE:MS)
Public Offering Advisors
Goodwin Procter LLP, Osler, Hoskin & Harcourt LLP, PricewaterhouseCoopers LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:20 AM
FUSN
Fusion Pharmaceuticals Inc 2023_10_05
Reports
14
CFRA Equity Research

Oct 04, 2023 03:40 AM
FUSN
Fusion Pharmaceuticals Inc.
Reports
9
William Blair & Company L.L.C.
Hsieh, Tsan-Yu
Oct 02, 2023 12:09 PM
FUSN
Reminder: William Blair’s Innovator Series: Radiopharmaceuticals – Virtual Event on October 4 and 5 From 9 a.m. to 1 p.m. ET
Reports
5
ValuEngine, Inc.

Oct 02, 2023 04:25 AM
FUSN
ValuEngine Rating and Forecast Report for FUSN
Reports
11
Oppenheimer & Co. Inc.
Jones, Jeffrey Michael
Sep 28, 2023 02:11 PM
FUSN
Diverse Clinical-Stage Portfolio Positions FUSN as a Radiopharm Leader: Initiate at Outperform, PT $13
Initiation of Coverage*
46
William Blair & Company L.L.C.
Hsieh, Tsan-Yu
Sep 27, 2023 05:30 AM
FUSN
Reminder: William Blair’s Innovator Series: Radiopharmaceuticals – Virtual Event on October 4 and 5 From 9 a.m. to 1 p.m. ET
Reports
4
GlobalData

Sep 21, 2023 05:46 AM
FUSN
Fusion Pharmaceuticals Inc (FUSN.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
65
William Blair & Company L.L.C.
Hsieh, Tsan-Yu
Sep 20, 2023 02:00 PM
FUSN
William Blair’s Innovator Series: Radiopharmaceuticals – Hosting Virtual Event on October 4 and 5 From 9 a.m. to 1 p.m. ET
Reports
4
GlobalData

Sep 15, 2023 04:36 AM
FUSN
Fusion Pharmaceuticals Inc (FUSN.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
58
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 13, 2023 06:00 PM
FUSN
Rating Update for Fusion Pharmaceuticals Inc
EPS Estimates*
3


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Federated Hermes, Inc.

10,633,789

15.41

49.7

Jun-30-2023


Avidity Partners Management, L.P.

5,700,000

8.26

26.6

Jun-30-2023


FMR LLC

4,681,457

6.78

21.9

Jun-30-2023


Odlander, Fredrikson & Co. AB

3,807,247

5.52

17.8

Feb-17-2023


Johnson & Johnson Innovation - JJDC, Inc.

3,670,516

5.32

17.1

Jun-30-2023


Siemens Aktiengesellschaft

3,256,972

4.72

15.2

Feb-17-2023


OrbiMed Advisors LLC

3,122,770

4.53

14.6

Jun-30-2023


Canada Pension Plan Investment Board

3,116,966

4.52

14.6

Jun-30-2023


Adams Street Partners, LLC

2,947,809

4.27

13.8

Jun-30-2023


Deerfield Management Company, L.P. Series C

2,823,000

4.09

13.2

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Federated Hermes, Inc.
10,633,789
4,784,689
Eagle Health Investments LP
680,370
680,370
Ghost Tree Capital, LLC
412,699
62,699
Sphera Funds Management Ltd
1,329,258
45,721
UBS O'Connor LLC
274,568
32,542

Top Sellers
Sellers
Common Stock Equivalent Held
Change
RA Capital Management, L.P.
0
(659,992)
Artal Group S.A.
1,725,000
(250,000)
Millennium Management LLC
334,577
(69,211)
Two Sigma Investments, LP
31,154
(13,673)
Virtu Financial LLC, Asset Management Arm
0
(13,084)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
FPI-1434 (Future), FPI-1547 (Future), FPI-1966 (Future), FPI-2059 (Future), FPI-2068 (Future), FPI-2107 (Future), FPI-2265 (Future)


Upcoming Events
Date/Time
Type
Nov-08-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-08-2023
Jun-30-2023
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEDAR
Interim Financial Statements
642 KB
Aug-08-2023
-
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEDAR
News Releases
147 KB
Aug-08-2023
Jun-30-2023
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEC
10-Q
12 MB
Aug-08-2023
Aug-08-2023
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEC
8-K (2.02, 9.01)
415 KB
Jun-27-2023
Jun-26-2023
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEC
8-K (7.01, 8.01, 9.01)
10 MB
Jun-20-2023
Jun-14-2023
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEC
8-K (5.07)
242 KB
Jun-16-2023
-
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEC
S-3
435 KB
Jun-15-2023
-
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEDAR
Management Proxy Materials
139 KB
May-11-2023
Mar-31-2023
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEDAR
Interim Financial Statements
1 MB
May-11-2023
Mar-31-2023
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
SEC
10-Q
12 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Khuong, Chau Quang (Independent Director)
Nov-11-2022
Common Shares
42,093
137,026
Other Acquisition
New
Form 4
Gannon C.A., CPA, CA, Steven R. (Independent Director)
Aug-11-2022
Common Shares
44,400
123,281
Open Market Acquisition
370.00
Form 4
Centre For Probe Development And Commercialization
Apr-27-2022
Common Shares
(4,511)
(37,205)
Disposition Under Employee Benefit Plan
(1.40)
Multiple
Valliant Ph.D., John F. (Founder, CEO & Director)
Apr-25-2022 - Apr-26-2022
Common Shares
(4,183)
(34,618)
Disposition Under Employee Benefit Plan
(1.28)
Multiple
-
Apr-26-2022
Common Shares
(2,147)
(17,825)
Disposition Under Employee Benefit Plan
-
Exchange Announcement
-
Apr-25-2022
Common Shares
(2,036)
(16,792)
Disposition Under Employee Benefit Plan
-
Exchange Announcement
Valliant Ph.D., John F. (Founder, CEO & Director)
Apr-20-2022 - Apr-21-2022
Common Shares
(1,289)
(10,601)
Disposition Under Employee Benefit Plan
(0.39)
Multiple
-
Apr-20-2022
Common Shares
(367)
(3,022)
Disposition Under Employee Benefit Plan
-
Exchange Announcement
-
Apr-21-2022
Common Shares
(922)
(7,579)
Disposition Under Employee Benefit Plan
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Duncan, Barbara G.
Independent Chairperson of the Board
289 799 0891
-

Valliant, John F.
Founder, CEO & Director
(617) 420-5698
-

Cagnoni, Pablo J.
Independent Director
(617) 679-9600
-

Gannon, Steven R.
Independent Director
289 799 0891
-

Bergstrom, Donald A.
Independent Director
289 799 0891
-

Christenson, Johan 
Independent Director
+46 70 97 59 866
-
johan.christenson@healthcap.eu
Juergens, Rosalyn 
Member of Advisory Board
-
-
-
Khuntia, Deepak 
Member of Advisory Board
-
-

Khuong, Chau Quang
Independent Director
289 799 0891
-
khuongc@orbimed.com
Lee, Philina 
Independent Director
289 799 0891
-

O’Bryan-Tear, Gillies 
Member of Advisory Board
-
-
-
Preston, Heather 
Independent Director
289 799 0891
-
hpreston@tpgventures.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Valliant, John F.
Founder, CEO & Director
(617) 420-5698
-

Rawat, Mohit 
President & Chief Business Officer
-
-

Crowley, John J.
Chief Financial Officer
-
-

Burak, Eric 
Chief Technology Officer
-
-

Leamon, Christopher Paul
Chief Scientific Officer
-
-

Cray, Amanda 
Senior Director of Investor Relations & Corporate Communications
617-967-0207
-
cray@fusionpharma.com
Stahl, Maria D.
Chief Legal Officer
(617) 926-3557
-
stahl@fusionpharma.com
Bobilev, Dmitri 
Chief Medical Officer
289 799 0891
-

Ferreira, Cara 
Chief of Staff
-
-

Hoffman, Eric S.
Senior Vice President of Business Development
-
-

Schindler, Joanne 
Executive Vice President of Medical Director & Clinical Development
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
